Biofrontera Reports Improved Financial Results with $12M in Revenue and Reduced Net Loss

Biofrontera Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $604,000, a significant improvement compared to a net loss of $5.3 million in the same period last year. The company generated product revenues of $12.0 million for the three months ended June 30, 2026, marking a 32.9% increase from $9.0 million in the prior year. This growth was primarily driven by a 30% increase in unit sales of its flagship product, Ameluz®, attributed to improved sales execution and strategic management, as well as accelerated orders in anticipation of supply restrictions due to ongoing legal matters.

In terms of operating expenses, Biofrontera reported a total of $12.5 million for the second quarter, down from $14.1 million in the previous year, reflecting a decrease in costs associated with revenues and selling, general, and administrative expenses. The cost of revenues from related parties decreased by 8.2% to $2.2 million, largely due to a new cost structure established through a strategic transaction with Biofrontera AG, which replaced a previous transfer pricing model. The company also recognized a patent remediation expense of $392,000 related to the International Trade Commission (ITC) matter, which has impacted its operations.

As of June 30, 2026, Biofrontera's total assets stood at $24.1 million, down from $28.6 million at the end of 2025. The company reported cash and cash equivalents of $4.7 million, a decrease from $6.4 million at the end of the previous fiscal year. The decline in cash reserves is attributed to ongoing operational losses, although the company has managed to reduce cash outflows from operations to $1.7 million in the first half of 2026, compared to $7.2 million in the same period of 2025.

Strategically, Biofrontera has focused on expanding its commercialization efforts for Ameluz® in the U.S. market while managing expenses. The company has also been navigating legal challenges, including a recent ITC ruling that prohibits the importation and sale of its RhodoLED® XL lamp, which has necessitated adjustments in its product offerings. Despite these challenges, management remains optimistic about achieving profitability through increased sales and potential milestone payments from the sale of its Xepi product line.

Looking ahead, Biofrontera plans to continue its efforts to expand market share and improve operational efficiencies. However, the company has expressed concerns regarding its liquidity and ability to sustain operations over the next twelve months without additional financing. Management is exploring various options, including drawing on a working capital line of credit and securing further capital through equity or debt financing to support its growth initiatives and research and development programs.